Glenmark's melogliptin set for Phase III studies
This article was originally published in Scrip
Executive Summary
Glenmark's oral dipeptidyl peptidase IV (DPP IV) inhibitor for type 2 diabetes, melogliptin, is expected to enter Phase III studies by the end of the year.